A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin.
Condition or disease
Cohorts of three patients each are treated at escalating doses of intravenous nystatin, administered every other day, until the MTD is reached. Each cohort is observed for toxicity for at least 2 weeks before escalation in subsequent patient cohorts is initiated.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Aerosolized pentamidine (300 mg once a month) for PCP prophylaxis in patients with CD4 count <= 200 cells/mm3. (Patients with CD4 count > 200 cells/mm3 who are already on aerosolized pentamidine may continue such therapy at the discretion of the investigator.)
Prophylaxis against Mycobacterium avium Complex in patients with CD4 count <= 100 cells/mm3.
Local treatment for Kaposi's sarcoma lesions with less than 25 percent increase in measurable disease.
Patients must have:
HIV antibody positivity.
Absolute CD4 count < 500 cells/mm3 on two determinations within 15 days prior to study entry.
At least 6 months of prior zidovudine (AZT) therapy.
No active opportunistic infection requiring ongoing therapy.
Normal neurologic status by standard assessment.
Life expectancy of at least 6 months.
Patients with the following symptoms and conditions are excluded:
Neoplasm other than basal cell carcinoma of the skin or stable untreated HIV-related Kaposi's sarcoma (provided there is no progression in the Kaposi's sarcoma beyond 25 percent of measurable disease).
Clinically significant cardiac disease.
Known hypersensitivity to polyene antibiotics.
Patients with the following prior conditions are excluded:
History of myocardial infarction or arrhythmias.
Excluded within 2 weeks prior to study entry:
Antiretroviral agents or interferons.
Biological response modifiers.
Cytotoxic chemotherapeutic agents.
Drugs that can cause neutropenia or significant nephrotoxicity.
Rios A, Brewton G, Crofoot G, Quesada J, Lenk R, Lopez-Berenstein G. A phase I-II clinical study of Nystatin-LF IV in patients with HIV infections. Int Conf AIDS. 1993 Jun 6-11;9(1):483 (abstract no PO-B26-2089)